We review the results of the phase I Graybug study Altissimo using sustained release tyrosinase kinase inhibitor for long term treatment of neovascular AMD with Dr. Veeral Sheth, Chicago, Illinois, Assistant Clinical Professor University of Illinois at Chicago.

The fluocinolone implant at 3 years is a useful modality for treating diabetic macular edema. Discussion with Dr. Michael Singer, Adjunct Professor University of Texas at San Antonio.

We discuss the DAVIO trial of EYP-1901 with Dr. Jay S. Duker, Chief Operating Officer of Eyepoint Pharmaceuticals.

We review the results of the KS-301 wet macular degeneration trial with Dr. Carl Regillo,
Chief of the Retina Service at Wills Eye Hospital

Phase I results of suprachoroidal delivery of a gene vector in treating neovascular AMD are promising. A discussion with Nikolas London, MD from  Retina Consultant Group in San Diego CA & Scripps Memorial Hospital La Jolla. 

Discussion of variations in injection volume for treatment of nAMD, DME and MERVO with Roger Goldberg, M.D., M.B.A.,  Bay Area Retina Associates

We examine the role of residual IRF and SRF in visual acuity results in treating nAMD. Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida reviews the results of the Hawk and Harrier trials.

We discuss the use of the newly approved Susvimo system for sustained delivery of ranibizumab in the treatment of neovascular AMD with Carl Regillo, MD, Professor of Ophthalmology Thomas Jefferson University and Director of the Retina Service at the Wills Eye Hospital.

We discuss the pathophysiology and techniques associated with subchoroidal administration of drugs and gene therapy vectors with James Major, MD, Ph.D., Retina Consultants of Texas and Houston Methodist Hospital.

We discuss the newly approved Xipere system for suprachoroidal administration of triamcinolone for treatment of macular edema associated with uveitis with Dr. Steven Yeh